Showing results (461-470 of 531) with videos related to
Sort By:
Pageof 54
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.Academic Radiology|August 13, 2013
Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphomaFernando Arias-Mendoza, Geoffrey S Payne, Kristen Zakian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.Blood Advances|February 12, 2020
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCLRakesh Awasthi, Lida Pacaud, Edward Waldron, et al.Lancet (London, England)|June 9, 2023
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 studyTanya Siddiqi, David G Maloney, Saad S Kenderian, et al.JCI Insight|September 22, 2022
Lower SARS-CoV-2-specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19Daniel J Schuster, Shelly Karuna, Caroline Brackett, et al.Blood Advances|July 31, 2023
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphomaMichael Scordo, Jessica R Flynn, Mithat Gonen, et al.Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaStephen J Schuster, Sattva S Neelapu, Barry L Gause, et al.Pageof 54